Boston Scientific (BSX) Tops Q4 EPS by 2c, FY EPS Guidance Trails Views at Mid-Point

Boston Scientific (NYSE: BSX) reported Q4 EPS of $0.39, $0.02 better than the analyst estimate of $0.37. Revenue for the quarter came in at $2.56 billion versus the consensus estimate of $2.56 billion.

GUIDANCE:

Boston Scientific sees Q1 2019 EPS of $0.35-$0.36, versus the consensus of $0.37.

• The company estimates revenue growth for the first quarter of 2019, versus the prior year period, to be in a range of approximately 6 to 7 percent on a reported basis and a growth range of approximately 7 to 8 percent on an organic basis, excluding the impact of changes in foreign currency exchange rates and contribution of approximately 160 basis points from the acquisitions of NxThera, Claret and Augmenix, each with no prior year comparable sales. The company estimates earnings on a GAAP basis in a range of $0.32 to $0.33 per share and estimates adjusted earnings, excluding amortization expense, acquisition-related, restructuring- and restructuring-related and litigation-related net charges (credits) in a range of $0.35 to $0.36 per share.

Boston Scientific sees FY2019 EPS of $1.53-$1.58, versus the consensus of $1.58.

• The company estimates revenue growth for the full year 2019, versus the prior year period, to be in a range of approximately 7 to 9 percent on a reported basis and a growth range of approximately 7 to 8.5 percent on an organic basis, excluding the impact of changes in foreign currency exchange rates and contribution of approximately 110 basis points from the acquisitions of NxThera, Claret and Augmenix, each with no prior year comparable sales. The company estimates income on a GAAP basis in a range of $1.13 to $1.18 per share and estimates adjusted earnings, excluding amortization expense, acquisition-related, restructuring- and restructuring-related and litigation-related net charges (credits) in a range of $1.53 to $1.58 per share.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• AXT appoints Tracy Liu to its board of directors